Establishment Labs Holdings Inc. cash flow to debt ratio of -19.24% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Establishment Labs Holdings Inc.'s free cash flow has increased -22.23% from $-74.08M last year to $-57.61M, signaling increasing performance

Establishment Labs Holdings Inc.'s debt to equity ratio is 12.20, which means that the company's assets are unhealthy financed, signaling financial risk.

Establishment Labs Holdings Inc.'s debt has increased relative to shareholder equity from 4.24 last year to 12.20 today, signaling weakened financials

Establishment Labs Holdings Inc. has negative EBITDA, making leverage ratio unreliable

Establishment Labs Holdings Inc.'s interest coverage ratio is -0.68, which means that the company struggles to meet interest obligations, signaling financial risk.

Establishment Labs Holdings Inc.'s profit margin has increased (-68.95%) in the last year from -50.95% to -15.82%, signaling increasing performance

Establishment Labs Holdings Inc.'s short-term assets of $249.94M exceed its short-term liabilities of $82.14M

Establishment Labs Holdings Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Establishment Labs Holdings Inc.'s return on equity of -203.88%, is lower than 15.00%, indicating bad performance

Establishment Labs Holdings Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Establishment Labs Holdings Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Establishment Labs Holdings Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Establishment Labs Holdings Inc. has negative free cash flow, indicating cash burn

Establishment Labs Holdings Inc.'s yearly earnings has increased -39.64% since last year from $-84.60M to $-51.06M, signaling increasing performance

Establishment Labs Holdings Inc.'s yearly revenue has increased 27.14% since last year from $166.03M to $211.08M, signaling increasing performance

ROIC -5.35% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Establishment Labs Holdings Inc.'s 3-year revenue CAGR of 9.29% is positive, indicating growing revenue over the past 3 years

Establishment Labs Holdings Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Establishment Labs Holdings Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Establishment Labs Holdings Inc. has insufficient data to evaluate this check.

Establishment Labs Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Establishment Labs Holdings Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Establishment Labs Holdings Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Establishment Labs Holdings Inc. is overvalued relative to its fair value price of -33.82 based on Earnings Fair Value model

Establishment Labs Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Establishment Labs Holdings Inc. has a price-to-book ratio of 104.64x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Establishment Labs Holdings Inc. has a price-to-sales ratio of 9.20x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue